Combining the current standard-of-care chemotherapy drug with a genetic inhibitor may improve treatment for pancreatic ductal adenocarcinoma, according to a recent study published in PNAS.
A newly discovered function of an epigenetic regulator could be a key to new cancer treatments, according to a new study published in Genes and Development.
A group of scientists combined medicinal chemistry and human stem cells to improve a medication treating a cardiac rhythm disorder, a strategy that could be applied broadly.
New findings have revealed previously unknown information about the genetic basis for Armfield XLID syndrome, a rare intellectual disability linked to genetic defects in the X chromosome.
The DNA methylation landscape of regulatory T-cells is more complex than previously understood, according to a new Northwestern Medicine study.
A new immunotherapy treatment for recurrent B-cell lymphoma was found to be safe in a trial of nearly 350 patients, according to a study published in The Lancet.
Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.
Biological sex has a small but ubiquitous influence on gene expression in almost every type of human tissue, according to a new study.
Targeting oxidative stress with a genetic therapy reduced atrial fibrillation in animal models of disease, making this a promising future treatment, according to a study published in Circulation.
Genomic alterations in prostate cancer therapeutic targets were found to be similar between African American and European American men, suggesting that existing precision medicine approaches could equally benefit both groups if applied equitably, according to a recent study.